Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Sponsor: Sun Pharma Japan Limited
Summary
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2026-06-19
Completion Date
2028-09
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Interventions
Deuruxolitinib
Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
Placebo
Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks
Locations (18)
Study Site 102
Asahikawa, Japan
Study Site 117
Bunkyō City, Japan
Study Site 119
Ebina, Japan
Study Site 101
Hamamatsu, Japan
Study Site 116
Ishikawa, Japan
Study Site 112
Kitakyushu, Japan
Study Site 118
Kōtoku, Japan
Study Site 110
Kurashiki, Japan
Study Site 113
Kurume, Japan
Study Site 107
Kyoto, Japan
Study Site 106
Mitaka-shi, Japan
Study Site 114
Miyagi-gun, Japan
Study Site 104
Niigata, Japan
Study Site 109
Osaka, Japan
Study Site 108
Osaka, Japan
Study Site 103
Sapporo, Japan
Study Site 105
Shinjuku-Ku, Japan
Study Site 111
Ube, Japan